Results 131 to 140 of about 52,949 (209)

Early-Phase Activation of Epithelial-Mesenchymal Transition in Lung Cancer Cells Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. [PDF]

Int J Mol Sci
Belloni A, Tamberi L, Graciotti L, Spadoni T, Matacchione G, Giordani C, Giuliani A, Chiadini E, Capelli L, Donno E, Sbrighi C, Zanoni M, Ulivi P, Rippo MR, Crinò L, Canale M, Bronte G.   +16 more
europepmc   +1 more source

Design, synthesis, and preliminary anticancer evaluation of diphenylpropan-1-one derivatives: <i>in vitro</i>, <i>in vivo</i> and <i>in silico</i> studies. [PDF]

RSC Adv
Najmi A, Alam MS, Ahsan W, Zoghebi K, Mohan S, Thangavel N, Taha MME, Ashafaq M, Bakht MA, Meraya A, Albratty M.   +10 more
europepmc   +1 more source

A Comparative Analysis of the Action Mechanisms of Cannabidiol, Cannabigerol, and Cannabinol in Human Cholangiocarcinoma Cell Lines. [PDF]

Molecules
Laprom S, Shuntawiwat B, Rattanacheeworn P, Jaisin Y, Choowongkomon K, Samatiwat P.   +5 more
europepmc   +1 more source

Maximizing Lipidome Coverage of Mouse Liver Following the IV Administration of Gefitinib by Combining Both UHPLC-MS-Based Untargeted and Targeted Lipidomics. [PDF]

J Proteome Res
Plumb RS, Munjoma N, Gethings LA, Wilson ID.   +3 more
europepmc   +1 more source

MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells. [PDF]

Cells
Ignoto B, Parisi IA, Roma C, Camerlingo R, Dotolo S, Tufano S, Maiello MR, Normanno N, Morabito A, De Luca A, Frezzetti D.   +10 more
europepmc   +1 more source

Retraction: The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting miR-377/CASP1 axis. [PDF]

Biosci Rep
Wang Z, Pan L, Yu H, Wang Y.
europepmc   +1 more source

Rash associated with epidermal growth factor receptor inhibitors: a systematic review and meta-analysis of 194 randomized controlled trials. [PDF]

Front Immunol
Zhao F, Qiu R, Liu Y, Zhang G, Chen S, Shu Q.   +5 more
europepmc   +1 more source

Gefitinib treatment after exfoliative dermatitis induced by sequential aumolertinib and furmonertinib in lung adenocarcinoma: a case report. [PDF]

Front Oncol
Xiang W, Hu X, Wei J, Cheng Z, Dong X.
europepmc   +1 more source

Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials. [PDF]

J Egypt Natl Canc Inst
Mahato S, Mudgal S, Singh H, Varikasuvu SR, Kumar H, Thankachan J, Kumar S.   +6 more
europepmc   +1 more source

Eyelash trichomegaly and durable complete response in a patient with metastatic lung adenocarcinoma receiving tyrosine kinase inhibitors: a case report. [PDF]

J Med Case Rep
Baghdad A, Ali K, Alali M, Saifo M.
europepmc   +1 more source